June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Metamorphopsia measurement with AMD - A Metamorphopsia Detector® as a patient reported outcome (PRO) measure
Author Affiliations & Notes
  • Ronald V Krüger
    CEO, app4eyes, Duesseldorf, NRW, Germany
  • Daniela Claessens
    CEO, app4eyes, Duesseldorf, NRW, Germany
  • Footnotes
    Commercial Relationships   Ronald Krüger, app4eyes (I); Daniela Claessens, app4eyes (I)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1522. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ronald V Krüger, Daniela Claessens; Metamorphopsia measurement with AMD - A Metamorphopsia Detector® as a patient reported outcome (PRO) measure. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1522.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Metamorphopsia as a patient reported outcome can be documented by the computer based interactive program AMD - A Metamorphopsia Detector® (patent pending). This study was performed to compare metamorphopsia measurement by AMD - A Metamorphopsia Detector® with results of the National Eye Institute Visual Function Questionnaire- 25 (NEI-VFQ 25) reflecting vision related quality of life.

Methods : 75 patients with unilateral metamorphopsia performed monocular metamorphopsia measurement with AMD – A Metamorphopsia Detector®. The software uses the concept of a negative image: a distorted image can be straightened by moving the mouse. Amplitude, localization and area of distorted lines are transformed into single dimensions and summarized in a global value. All patients were asked to fill out the NEI-VFQ 25: response rate was 56% (n=42, caucasian, age 40-86 years, 19 male, 23 female). In all responding patients (macular edema due to age related macular degeneration=22, central venous thrombosis=2, diabetes=3, uveitis=4, intermediate AMD=7, macular pucker=4) correlation of NEI-VFQ 25 (subscale near vision) on the one side and global value / single dimensions of Metamorphopsia measurement with AMD - A Metamorphopsia Detector® as a patient reported outcome were measured. Visual acuity of the partner eye was taken into account as a potential confounder. Prior to the study all patients signed informed consent according to the declaration of Helsinki/Edinburgh.

Results : Correlation of metamorphopsia global value with subscale near vision of NEI VFQ 25 was very high: Pearson correlation coefficient ρ = -0,87 (95% confidence interval: -0.93;-0.77, p < 0.001).
Correlation of metamorphopsia single dimensions with NEI VFQ 25 was very high: ρ = -0.85 (CI: -0.92;-0.74, p < 0.001) / ρ = -0,82 (CI: -0.9;-0.7, p < 0.001) / ρ = -0.71 (CI: -0.86;-0.57, p < 0.001) for amplitude, localization and area of distortion.

Conclusions : As a quantitative test highly correlating with vision related quality of life AMD – A Metamorphopsia Detector® can deliver information about a patient reported outcome in macular disease.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

Metamorphopsia Detector

Metamorphopsia Detector

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×